Cumulative incidence of infection with competing events following CD19 CAR T-cell therapy for R/R B-ALL. (A) Any infection; (B) bacterial infection; (C) viral infection; (D) fungal infection.
Figure 2.

Cumulative incidence of infection with competing events following CD19 CAR T-cell therapy for R/R B-ALL. (A) Any infection; (B) bacterial infection; (C) viral infection; (D) fungal infection.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal